| II-35 Mats Magnusson Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis Wednesday 15:10-16:40 |
| II-35 Mats Magnusson Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis Wednesday 15:10-16:40 |